[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338505-105":59,"doc-detail-338505-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","reactivation-of-mapk-sox2-pathway-confers-ferroptosis-sensitivity-in-krasg12c-inhibitor-resistant-tumors","Reactivation of MAPK-SOX2 pathway confers ferroptosis sensitivity in KRASG12C inhibitor resistant tumors","","Clinical success of KRASG12C inhibitors, including AMG510 and MRTX849, is constrained by acquired resistance. The study generated AMG510- and MRTX849-resistant KRASG12C mutant cancer cell lines and screened an FDA-approved drug library, identifying ferroptosis inducers such as sorafenib and lapatinib as strong growth inhibitors. Mechanistically, resistant cells reactivate MAPK signaling, suppressing SOX2-dependent SLC7A11 and SLC40A1 expression. This lowers GSH and raises iron, creating ferroptosis hypersensitivity, while SOX2 or SLC7A11/SLC40A1 overexpression reverses resistance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/reactivation-of-mapk-sox2-pathway-confers-ferroptosis-sensitivity-in-krasg12c-inhibitor-resistant-tumors/338505/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/reactivation-of-mapk-sox2-pathway-confers-ferroptosis-sensitivity-in-krasg12c-inhibitor-resistant-tumors/338505.png","ImageObject",300,407,{"name":92,"@type":93},"Evangeline","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are KRASG12C inhibitors limited in patients?","Question",{"text":112,"@type":113},"Their clinical benefit is limited by the eventual development of acquired resistance.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What drug class showed prominent effects in KRASG12C inhibitor-resistant cells?",{"text":117,"@type":113},"Ferroptosis inducers, including sorafenib and lapatinib, produced clear growth inhibition in the resistant cells.",{"name":119,"@type":110,"acceptedAnswer":120},"How does MAPK-SOX2 signaling relate to ferroptosis sensitivity in resistant tumors?",{"text":121,"@type":113},"Reactivated MAPK signaling represses SOX2-mediated expression of SLC7A11 and SLC40A1, resulting in low intracellular GSH and high iron, which increases ferroptosis sensitivity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338505,1790277383,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","Redox Biology 78 (2024) 103419  \nContents lists available at ScienceDirect  \nRedox Biology  \njournal [homepage:](homepage: www.elsevier.com/locate/redox)[ www.elsevier.com/locate/redox](homepage: www.elsevier.com/locate/redox)  \n| Reactivation of MAPK-SOX2 pathway confers ferroptosis sensitivity in KRASG12C inhibitor resistant tumors\u003Cbr>Kai Wang a,1, Xin Zhang a,1, Yufei Fan a, Liang Zhou b, Yajun Duan a, Su Li a, Zhongkan Sun a, Chunqian Zhang a, Haoyu Yang a, Wenxiu Yuan a, Linyuan Peng a, Xiaoyu Ma a, Siliang Xiang a, Tianzhi Wang a, Mei Yang a, Zhenyuan Zhang a, Jiaxuan Wang a, Zhongyuan Wang a,*,\u003Cbr>**\u003Cbr>Minxian Qian a,\u003Cbr>a State Key Laboratory of Natural Medicines, Department of Life Science and Technology, China Pharmaceutical University, Nanjing, 211198, China\u003Cbr>b MOE Key Laboratory of Gene Function and Regulation, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, 510275, China |  |  |\n| --- | --- | --- |\n| A R T I C L E I N F O |  | A B S T R A C T |\n| Keywords:\u003Cbr>KRAS\u003Cbr>Resistance Ferroptosis KRASG12C inhibitors AMG510\u003Cbr>MRTX849 |  | The clinical success of KRASG12C inhibitors (G12Ci) including AMG510 and MRTX849 is limited by the eventual development of acquired resistance. A novel and effective treatment to revert or target this resistance is urgent. To this end, we established G12Ci (AMG510 and MRTX849) resistant KRASG12C mutant cancer cell lines and screened with an FDA-approved drug library. We found the ferroptosis inducers including sorafenib and lapatinib stood out with an obvious growth inhibition in the G12Ci resistant cells. Mechanistically, the G12Ci resistant cells exhibited reactivation of MAPK signaling, which repressed SOX2-mediated expression of cystine transporter SLC7A11 and iron exporter SLC40A1. Consequently, the low intracellular GSH level but high iron content engendered hypersensitivity of these resistant tumors to ferroptosis inducers. Ectopic overexpression of SOX2 or SLC7A11 and SLC40A1 conferred resistance to ferroptosis in the G12Ci resistant cells. Ferroptosis induced by sulfasalazine (SAS) achieved obvious inhibition on the tumor growth of xenografts derived from AMG510-resistant KRASG12C-mutant cells. Collectively, our results suggest a novel therapeutic strategy to treat patients bearing G12Ci resistant cancers with ferroptosis inducers. |\n\n1. Introduction  \nKRAS is a membrane-associated small GTPase and mutated in approximately 15 % of all human tumors. As a molecular switch, KRASinterconverts between active GTP-bound and inactive GDP-bound forms to gate signaling pathways. This process is tightly controlled by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs) [1]. Oncogenic mutations ofKRAS always occur at codons 12, 13 and 61 and keep KRAS in a constitutively active GTP-bound state for the inability to hydrolyze GTP, leading to hyperactivation of downstream signaling by RAF, MEK, ERK, PI3K and other kinases, thus driving uncontrolled cellular proliferation, transformation and eventually tumorigenesis [2,3]. Therefore, targeting mutant KRAS is a promising therapeutic strategy for cancer treatment.  \nHowever, KRAS has long been considered as an undruggable target  \nuntil the recent success of several irreversible covalently binding inhibitors targeting KRASG12C, a mutation occurs commonly in non-small cell lung cancers (NSCLCs) and at a lower frequency in other tumors [4]. Intriguingly, both AMG510 and MRTX849 have been granted approval by the US Food and Drug Administration (FDA) for the treatment of KRASG12C-mutant NSCLCs [5,6]. Although both AMG510 and MRTX849 exhibit clinical benefits in patients, with response rates of about 36 % for AMG510 and 53 % for MRTX849, adaptive and acquired resistance limits the therapeutic efficacy of the inhibitors [7,8]. Currently, several mechanisms of resistance have been explored including KRAS alterations and amplification, reactivation of ERK-dependent signaling,","cbCaio1YRQ0S3gti","https://ap.wps.com/l/cbCaio1YRQ0S3gti","pdf",17947870,13,"English","# Article Info\n## Keywords\n## Introduction","[{\"question\":\"Why are KRASG12C inhibitors limited in patients?\",\"answer\":\"Their clinical benefit is limited by the eventual development of acquired resistance.\"},{\"question\":\"What drug class showed prominent effects in KRASG12C inhibitor-resistant cells?\",\"answer\":\"Ferroptosis inducers, including sorafenib and lapatinib, produced clear growth inhibition in the resistant cells.\"},{\"question\":\"How does MAPK-SOX2 signaling relate to ferroptosis sensitivity in resistant tumors?\",\"answer\":\"Reactivated MAPK signaling represses SOX2-mediated expression of SLC7A11 and SLC40A1, resulting in low intracellular GSH and high iron, which increases ferroptosis sensitivity.\"}]","Reactivation of MAPK-SOX2 pathway confers ferroptosis sensitivity in KRASG12C inhibitor resistant tumors | PDF",1790023911,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/657eef5231757e2faa507654a48cdbd8.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/86ab64b9b31aa24104e1136b75ac0106.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5bcd1e6b35b6d49434984273c9149c3d.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e6145916a17d8a65502043937a58503.webp",980,1306]